VANTIN
What it isPBP-inhibiting third-generation oral cephalosporin prodrug; respiratory, skin, and urinary infections.
Why this oneBroader Gram-negative cover than the earlier oral cephalosporins with twice-daily dosing.
What limits itIt needs food and gastric acid for absorption, so PPIs and antacids reduce it. No pseudomonal or MRSA cover.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Pharyngitis/tonsillitis | Adults/adolescents ≥12 y | 100 mg q12h ×5–10 days | 100 mg q12h | |
| Acute community-acquired pneumonia | Adults/adolescents ≥12 y | 200 mg q12h ×14 days | 200 mg q12h | |
| Acute exacerbation of chronic bronchitis | Adults/adolescents ≥12 y | 200 mg q12h ×10 days | 200 mg q12h | |
| Uncomplicated gonorrhea; rectal gonococcal (women) | Adults/adolescents ≥12 y | 200 mg single dose | 200 mg single dose | |
| Skin/skin-structure infection | Adults/adolescents ≥12 y | 400 mg q12h ×7–14 days | 400 mg q12h | |
| Acute maxillary sinusitis | Adults/adolescents ≥12 y | 200 mg q12h ×10 days | 200 mg q12h | |
| Uncomplicated UTI | Adults/adolescents ≥12 y | 100 mg q12h ×7 days | 100 mg q12h |
Renal Severe impairment (CrCl <30 mL/min): extend dosing interval to q24h. Hemodialysis: 3 times/week after dialysis
Hepatic No adjustment needed
Pregnancy Not teratogenic/embryocidal in animals; no adequate human studies — use only if clearly needed
Lactation Undefined
NO BOXED WARNINGS
Principal riskHypersensitivity; needs food and acid for absorption
Cost, est. cash$5–$150/month
Generic entry2002
Legacy pregnancy categoryB
Defining liabilityAllergy, gastrointestinal effects and agent-specific renal, hepatic, hematologic or interaction risks.

Open Cefpodoxime in the interactive console ↗
